A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of nipocalimab compared to placebo in participants with generalized myasthenia gravis (gMG).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Detailed Description
Myasthenia gravis (MG) is a rare, heterogeneous, neuromuscular disease characterized by fluctuating, fatigable muscle weakness. MG is caused by pathogenic autoantibodies that impair cholinergic transmission in the postsynaptic membrane at the neuromuscular junction and impair or prevent muscle contraction. Nipocalimab (also referred to as JNJ-80202135 or M281) is a fully human, aglycosylated immunoglobulin (Ig)G1 monoclonal antibody (mAb) designed to selectively bind, saturate, and block the IgG binding site on the endogenous neonatal Fc receptor (FcRn). This study will consist of a screening phase (up to 4 weeks), treatment phase (a 24-week double-blind placebo-controlled phase, and an open-label extension [OLE] phase [up to 2 years]) and a follow-up safety visit (up to 8 weeks after last infusion of study intervention). Efficacy evaluations will include assessments such as Myasthenia Gravis
- Activities of Daily Living (MG-ADL) score. Safety evaluations (such as adverse events, physical examination, vital signs, electrocardiogram [ECG], and clinical laboratory tests) will be performed. The overall duration of study will be up to 4 years and 8 months.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Nipocalimab Double-blind Placebo-controlled Phase: Participants will receive nipocalimab intravenous (IV) infusions once every 2 weeks (q2w) up to 24 weeks during double-blind placebo-controlled phase. Open-label Extension (OLE) Phase: Participants who complete the double-blind placebo-controlled phase will enter the OLE phase and continue to receive nipocalimab q2w IV infusion from OLE Day 1 to 24 weeks. Participants who are stable on the q2w dosing regimen can opt in at principal investigator (PI) discretion to be transitioned to a dosing regimen every 4 weeks (q4w) during OLE phase. |
Drug: Nipocalimab
Nipocalimab will be administered as an IV infusion.
Other Names:
|
| Placebo Comparator: Placebo Double-blind Placebo-controlled Phase: Participants will receive matching placebo of nipocalimab IV infusion q2w up to 24 weeks during double-blind placebo-controlled phase. |
Drug: Placebo
Matching placebo will be administered as an IV infusion.
|
Outcome Measures
Primary Outcome Measures
- Average Change from Baseline in Myasthenia Gravis - Activities of Daily Living (MG-ADL) Score [Baseline up to Week 24]
Average change from baseline in MG-ADL score over Weeks 22, 23 and 24 of the double-blind placebo-controlled phase will be reported. Averaging over multiple time points (Weeks 22, 23 and 24) will be done to get a single measure. The MG-ADL provides a rapid assessment of the participant's MG symptom severity. Eight functions (talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, eyelid droop) are rated on a 4-point scale: 0 (no impairment) to 3 (severe impairment). The total score will be sum of eight function scores and can range from 0 to 24. A higher score indicates greater symptom severity.
Secondary Outcome Measures
- Average Change in Quantitative Myasthenia Gravis (QMG) Score Over Weeks 22 and 24 of the Double-blind Placebo-controlled Phase [Up to Weeks 22 and 24]
Average change in QMG score over Weeks 22 and 24 of the double-blind placebo-controlled phase will be reported. The QMG test is a standardized quantitative strength assessment comprising 13 components. The quantitative results of each strength component are mapped to the following 4-point scale: 0 equals to (=) none, 1 = mild, 2 = moderate and 3 = severe. The total score will be sum of 13 components scores and can range from 0 to 39. A higher score indicates greater weakness.
- Percentage of Participants whose Average MG-ADL Total Score Over Weeks 22, 23, and 24 is at least a 2-Point Improvement from Baseline of the Double-blind Placebo-controlled Phase [Baseline up to Weeks 22, 23 and 24]
Percentage of participants whose average MG-ADL total score over Weeks 22, 23, and 24 is at least a 2-point improvement from baseline of the double-blind placebo-controlled phase will be reported.
- Percentage of Participants with Improvement in MG-ADL Total Score Greater Than Or Equal to (>=) 2 Points at Week 1 and/or Week 2 of the Double-blind Placebo-controlled Phase [Weeks 1 and 2]
Percentage of participants with improvement in MG-ADL total score >= 2 points at Week 1 and/or Week 2 of the double-blind placebo-controlled phase will be reported.
- Average Percentage of Participants with MG-ADL Score of 0 or 1 Over Weeks 22, 23 and 24 of the Double-blind Placebo-controlled Phase [Up to Weeks 22, 23 and 24]
The average percentage of participants with MG-ADL score of 0 or 1 over Weeks 22, 23 and 24 of the double-blind placebo-controlled phase will be reported.
- Percentage of Participants with Improvement in MG-ADL Total Score >= 2 Points at Week 2 through Week 24 of the Double-blind Placebo-controlled Phase with No More Than 2 Excursions Allowed at Weeks 3 through 23 [Week 2 up to Week 24]
Percentage of participants with improvement in MG-ADL total score >= 2 points at Week 2 through Week 24 of the double-blind placebo-controlled phase with no more than 2 excursions allowed at Weeks 3 through 23 (excursion is defined as loss of improvement in MG-ADL score >= 2 points) will be reported.
- Percentage of Participants with Adverse Events (AEs) [Up to Week 24 of double-blind placebo-controlled phase and up to extension Week 24 of open-label extension phase (up to Week 48)]
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.
- Percentage of Participants with Serious Adverse Events (SAEs) [Up to Week 24 of double-blind placebo-controlled phase and up to extension Week 24 of open-label extension phase (up to Week 48)]
A SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a suspected transmission of any infectious agent via a medicinal product; is medically important.
- Percentage of Participants with Adverse Events of Special Interest (AESIs) [Up to Week 24 of double-blind placebo-controlled phase and up to extension Week 24 of open-label extension phase (up to Week 48)]
Percentage of participants with AESIs will be reported. Treatment-emergent AEs associated with the following situations are considered as AESI: 1) severe or medically significant or immediately life-threatening infections requiring intravenous (IV) anti-infective or operative/invasive intervention or requiring hospitalization or prolongation of existing hospitalization; 2) hypoalbuminemia with albumin less than (<) 20 grams per liter (g/L). Treatment-emergent AEs are defined as AEs with onset or worsening on or after date of first dose of study treatment.
- Percentage of Participants with Change in Vital Signs [Up to Week 24 of double-blind placebo-controlled phase and up to extension Week 24 of open-label extension phase (up to Week 48)]
Percentage of participants with change in vital signs (temperature, blood pressure and heart rate) will be reported.
- Percentage of Participants with Change in Clinical Laboratory Values [Up to Week 24 of double-blind placebo-controlled phase and up to extension Week 24 of open-label extension phase (up to Week 48)]
Percentage of participants with change in clinical laboratory (serum chemistry, hematology, lipid profiles and urinalysis) values will be reported.
- Percentage of Participants with Change in Columbia-Suicide Severity Rating Scale (C-SSRS) Score [Up to Week 24 of double-blind placebo-controlled phase and up to extension Week 24 of open-label extension phase (up to Week 48)]
Percentage of participants with change in C-SSRS scale score will be reported. C-SSRS is semi structured clinician-administered questionnaire designed to solicit the occurrence, severity, and frequency of suicide-related ideation and behaviors. Total score ranges from 1 to 10. Higher scores indicate greater severity.
- Percentage of Participants with Improvement in QMG Score of >= 3 Points from Baseline at Week 2 through Week 24 of the Double-blind Placebo-controlled Phase with No More than 2 Excursions Allowed at Weeks 4 through 22 [Week 2 up to Week 24]
Percentage of participants with improvement in QMG score of >= 3 points from baseline at Week 2 through Week 24 of the double-blind placebo-controlled phase with no more than 2 excursions allowed at weeks 4 through 22 (excursions defined as loss of improvement in QMG score of >= 3 points) will be reported.
- Average Change From Baseline in the Fatigue Items of the Quality of Life in Neurological Disorders Scale (Neuro-QoL Fatigue) Total Score Over Weeks 22 and 24 of Double-blind Placebo-controlled Phase [Baseline up to Weeks 22 and 24]
Average change from baseline in the Neuro-QoL Fatigue total score over Weeks 22 and 24 of double-blind placebo-controlled phase will be reported. Neuro-QoL fatigue is a 19-item questionnaire developed and validated for use in common neurological conditions which assesses patient-reported fatigue and associated impact on physical, mental, and social activities during the past 7 days. Each item included in the Neuro-QoL Fatigue questionnaire is graded on a 5-point Likert-type scale (1=Never; 2=Rarely; 3=Sometimes; 4=Often; 5=Always). The total scores are calculated by summing 19 items score and can range from 19-95. Higher score reflects more fatigue.
- Average Change from Baseline in the Revised Myasthenia Gravis Quality of Life - 15 Scale (MG-Qol15r) Score Over Weeks 22 And 24 of the Double-blind Placebo-controlled Phase [Baseline up to Weeks 22 and 24]
Average change from baseline in the MG-QoL15r score over Weeks 22 and 24 of the double-blind placebo-controlled phase will be reported. The MG-QoL15r is a participant-reported outcome instrument that measures MG-specific health-related quality of life. The MG-QoL15r contains 15 items that evaluate patients' experience related to Myasthenia Gravis over the "past few weeks" on a 3-point Likert-type scale (0=Not at all; 1=Somewhat; 2=Very much). The total score of the MG-QoL15r can be calculated by summing 15 items score and can range from 0 to 30. A higher score indicates poorer health related quality of life.
- Change from Baseline in the Visual Analog Scale (VAS) Score of European Quality of Life (EuroQol) 5-Dimension 5-Level (EQ-5D-5L) Scale Over 24 Weeks of the Double-blind Placebo-controlled Phase [Baseline up to 24 weeks]
Change from baseline in the VAS score of EQ-5D-5L scale over 24 weeks of the double-blind placebo-controlled phase will be reported. EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a scale of 0 (worst imaginable health state) to 100 (best imaginable health state). Positive change in score indicates improvement.
- Change from Baseline in the Health Status Index of the EQ-5D-5L Scale Over 24 Weeks of the Double-blind Placebo-controlled Phase [Baseline up to 24 weeks]
Change from baseline in health status index of EQ-5D-5L scale over 24 weeks of double-blind placebo-controlled phase will be reported. EQ-5D-5L is standardized instrument for use as measure of health outcome, primarily designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ-VAS. EQ-5D-5L descriptive system comprises following 5 dimensions: Mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of 5 dimensions is divided into 5 levels of perceived problems (1 indicating no problem, 2 indicating slight problems, 3 indicating moderate problems, 4 indicating severe problems, 5 indicating extreme problems). Participant selects an answer for each of 5 dimensions considering response that best matches his or her health "today". The responses to 5 dimensions are used to compute a single score ranging from zero (0.0- worst health state) to 1 (1.0- better health state) representing the general health status of the individual.
- Serum Nipocalimab Concentrations Over Time [Up to 4 years and 8 months]
Serum nipocalimab concentrations over time will be reported.
- Number of Participants with Antibodies to Nipocalimab (Anti-Drug Antibodies [ADAs] and Neutralizing Antibodies [NAbs]) [Up to 4 years and 8 months]
Number of participants with antibodies to nipocalimab (ADAs and NAbs) will be reported.
- Change in Total Serum Immunoglobulin G (IgG) Concentrations [Up to 4 years and 8 months]
Change in total serum IgG concentrations will be reported.
- Change in Levels of Autoantibodies Associated with Generalized Myasthenia Gravis (gMG) [Up to 4 years and 8 months]
Change in levels of autoantibodies associated with gMG will be reported.
- Change from Baseline in MG-ADL Score as a Function of IgG [Baseline up to 4 years and 8 months]
Change from baseline in MG-ADL score as a function of IgG will be reported.
- Change from Baseline in QMG Score as a Function of IgG [Baseline up to 4 years and 8 months]
Change from baseline in QMG score as a function of IgG will be reported.
- Change From Baseline in MG-ADL Score as a Response to Percent Change in Autoantibody Levels, in Seropositive Participants Treated with Nipocalimab [Baseline up to 4 years and 8 months]
Change from baseline in MG-ADL as a response to percent change in autoantibody levels, in seropositive participants (anti-acetylcholine receptor [anti-AChR], anti-muscle-specific kinase [anti-MuSK], anti-lipoprotein-related protein receptor 4 [anti-LRP4]) treated with nipocalimab will be reported.
- Change From Baseline in QMG Score as a Response to Percent Change in Autoantibody Levels, in Seropositive Participants Treated with Nipocalimab [Baseline up to 4 years and 8 months]
Change from baseline in QMG score as a response to percent change in autoantibody levels, in seropositive participants (anti-AChR, anti-MuSK, anti-LRP4) treated with nipocalimab will be reported.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Diagnosis of myasthenia gravis (MG) with generalized muscle weakness meeting the clinical criteria for generalized myasthenia gravis (gMG) as defined by the Myasthenia Gravis Foundation of America (MGFA) Clinical Classification Class II a/b, III a/b, or IVa/b at screening
-
Myasthenia Gravis - Activities of Daily Living (MG-ADL) score of greater than or equal to (>=) 6 at screening and baseline
-
Has sufficient venous access to allow drug administration by infusion and blood sampling as per the protocol
-
A woman of childbearing potential must have a negative highly sensitive serum (beta-human chorionic gonadotropin [beta-hCG]) at screening and a negative urine pregnancy test at Day 1 prior to administration of study intervention
-
A male participant must agree not to donate sperm for the purpose of reproduction during the study and for a minimum 90 days after receiving the last administration of study intervention
Exclusion Criteria:
-
Has any confirmed or suspected clinical immunodeficiency syndrome not related to treatment of his/her gMG, or has a family history of congenital or hereditary immunodeficiency unless confirmed absent in the participant
-
Has MGFA Class I disease or presence of MG crisis (MGFA Class V) at screening, history of MG crisis within 1 month of screening, or fixed weakness (and/or 'burnt out' MG)
-
Has had a thymectomy within 12 months prior to screening, or thymectomy is planned during the study
-
Has known allergies, hypersensitivity, or intolerance to nipocalimab or its excipients
-
Has experienced myocardial infarction, unstable ischemic heart disease, or stroke within 12 weeks of screening
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | IMC-Diagnostic and Medical Clinic | Mobile | Alabama | United States | 36604 |
| 2 | Neuromuscular Research Center and Clinic | Paradise Valley | Arizona | United States | 85028 |
| 3 | HonorHealth Neurology | Scottsdale | Arizona | United States | 85251 |
| 4 | University of Southern California | Los Angeles | California | United States | 90033 |
| 5 | Stanford University | Palo Alto | California | United States | 94304 |
| 6 | Care Access Research | Pasadena | California | United States | 91101 |
| 7 | University of Colorado - Anschutz Medical Campus | Aurora | Colorado | United States | 80045 |
| 8 | Yale New Haven Hospital | New Haven | Connecticut | United States | 06519 |
| 9 | FM Clinical Research, LLC South Florida Neurology Associates, P. A. | Boca Raton | Florida | United States | 33487 |
| 10 | University of Florida | Jacksonville | Florida | United States | 32209 |
| 11 | Medsol Clinical Research Center Inc | Port Charlotte | Florida | United States | 33952 |
| 12 | University of South Florida | Tampa | Florida | United States | 33612 |
| 13 | Augusta University | Augusta | Georgia | United States | 30912-3125 |
| 14 | University of Kansas Medical Center | Kansas City | Kansas | United States | 66160 |
| 15 | Ochsner Clinic Foundation | New Orleans | Louisiana | United States | 70121 |
| 16 | St. Elizabeth Medical Center | Boston | Massachusetts | United States | 02135 |
| 17 | Lahey Hospital & Medical Center | Burlington | Massachusetts | United States | 01805 |
| 18 | Washington University School of Medicine | Saint Louis | Missouri | United States | 63110 |
| 19 | Las Vegas Medical Research | Las Vegas | Nevada | United States | 89145 |
| 20 | Atrium Health | Charlotte | North Carolina | United States | 28078 |
| 21 | Duke University School of Medicine | Durham | North Carolina | United States | 27710 |
| 22 | University of Cincinnati | Cincinnati | Ohio | United States | 45219 |
| 23 | Cleveland Clinic | Cleveland | Ohio | United States | 44145 |
| 24 | The Ohio State University | Columbus | Ohio | United States | 43210 |
| 25 | Medical University of South Carolina | Charleston | South Carolina | United States | 29425 |
| 26 | Wesley Neurology | Cordova | Tennessee | United States | 38018 |
| 27 | UT Southwestern Medical Center | Dallas | Texas | United States | 75390 |
| 28 | University of Vermont | Burlington | Vermont | United States | 05401 |
| 29 | Townsville Hospital | Douglas | Australia | Queensland | |
| 30 | Melbourne Neurology Group | North Melbourne | Australia | 3051 | |
| 31 | Gold Coast University Hospital | Southport | Australia | 4215 | |
| 32 | ULB Hôpital Erasme | Anderlecht | Belgium | 1070 | |
| 33 | AZ Sint-Jan Brugge-Oostende AV | Brugge | Belgium | 8000 | |
| 34 | Cliniques Universitaires Saint Luc | Brussels | Belgium | 1200 | |
| 35 | AZ Sint-Lucas | Gent | Belgium | 9000 | |
| 36 | University Hospitals Leuven | Leuven | Belgium | 3000 | |
| 37 | Vancouver General Hospital | Vancouver | British Columbia | Canada | V5Z 1M9 |
| 38 | The Ottawa Hospital Research Institute | Ottawa | Ontario | Canada | K1Y 4E9 |
| 39 | Toronto General Hospital | Toronto | Ontario | Canada | M5G 2C4 |
| 40 | McGill University | Montreal | Quebec | Canada | H3A 2B4 |
| 41 | Beijing Tiantan Hospital, Capital Medical University | Beijing | China | 100050 | |
| 42 | Xuanwu Hospital, Capital Medical University | Beijing | China | 100053 | |
| 43 | Beijing Hospital | BeiJing | China | 100730 | |
| 44 | Peking Union Medical College Hospital | Beijing | China | 100730 | |
| 45 | The First Bethune Hospital of Jilin University | Changchun | China | 130021 | |
| 46 | Central South University Xiangya Hospital The First Affiliated Hospital of Hunan Medical College | Changsha | China | 410008 | |
| 47 | West China Hospital of Sichuan University | Chengdu | China | 610041 | |
| 48 | Fujian Medical University Union Hospital | Fuzhou | China | 350001 | |
| 49 | The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine | Guangzhou | China | 510405 | |
| 50 | Sir Run Run Shaw Hospital, Zhejiang University School of Medicine | Hangzhou | China | 310020 | |
| 51 | Qianfoshan hospital of Shandong Province | Jinan | China | 250014 | |
| 52 | Qilu Hospital of Shandong University | Jinan | China | 250014 | |
| 53 | Huashan Hospital Fudan University | Shanghai | China | 200040 | |
| 54 | Tianjin Medical University General Hospital | Tianjin | China | 300052 | |
| 55 | The Second Affiliated Hospital of Air Force Medical University - Tangdu Hospital | Xi'An | China | 710038 | |
| 56 | Medicity S.A.S | Bucaramanga | Colombia | 681012 | |
| 57 | Fundacion Cardiovascular de Colombia | Floridablanca | Colombia | 680004 | |
| 58 | Neurologie a rehabilitace Skopalíkova | Brno | Czechia | 615 00 | |
| 59 | Fakultni nemocnice Brno | Brno | Czechia | 625 00 | |
| 60 | Fakultni nemocnice Ostrava | Ostrava | Czechia | 70852 | |
| 61 | Vseobecna Fakultní Nemocnice | Praha | Czechia | 12808 | |
| 62 | Aalborg University Hospital | Aalborg | Denmark | 9000 | |
| 63 | Aarhus Universitetshospital | Aarhus | Denmark | DK-8200 | |
| 64 | Rigshospitalet | København Ø | Denmark | 2100 | |
| 65 | Hopital Pierre Wertheimer | Bron | France | 69500 | |
| 66 | CHU Grenoble | Grenoble | France | 38043 | |
| 67 | Hopital de la Pitie Salpetriere | Paris | France | 75013 | |
| 68 | Hopital PASTEUR | Provence-Alpes-Côte d'Azur | France | 06000 | |
| 69 | NeuroCure Clinical Research Center | Berlin | Germany | 10117 | |
| 70 | Kreiskrankenhaus Gummersbach | Gummersbach | Germany | 51643 | |
| 71 | Universitätsmedizin Göttingen | Göttingen | Germany | 37075 | |
| 72 | Universitätsklinikum Jena | Jena | Germany | 07743 | |
| 73 | Universitatsklinikum Leipzig | Leipzig | Germany | 04103 | |
| 74 | Universitätsklinikum Schleswig Holstein Campus Lübeck | Lübeck | Germany | 23538 | |
| 75 | Klinikum rechts der Isar der TU Munchen | München | Germany | 81675 | |
| 76 | Universitätsklinikum Ulm | Ulm | Germany | 89081 | |
| 77 | DKD HELIOS Klinik Wiesbaden, Fachbereich Neurologie | Wiesbaden | Germany | 65191 | |
| 78 | U.O.P.I. di Psichiatria | Catania | Italy | 95100 | |
| 79 | Fondazione Istituto G. Giglio | Cefalu | Italy | 90015 | |
| 80 | Istituto Neurologico Carlo Besta | Milano | Italy | 20133 | |
| 81 | Azienda Ospedaliera Univ.- Università Degli studi della Campania - Luigi Vanvitelli | Napoli | Italy | 80138 | |
| 82 | IRCCS C. Mondino, Istituto Neurologico Nazionale, Fondazione | Pavia | Italy | 27100 | |
| 83 | Azienda ospedaliera Sant'Andrea di Roma- Università di Roma La Sapienza | Roma | Italy | 00189 | |
| 84 | Policlinico Universitario Agostino Gemelli | Roma | Italy | 168 | |
| 85 | Chiba University Hospital | Chiba | Japan | 260-8677 | |
| 86 | General Hanamaki Hospital | Hanamaki | Japan | 025-0082 | |
| 87 | Hiroshima University Hospital | Hiroshima-shi | Japan | 734-8551 | |
| 88 | St.Marianna University Hospital | Kawasaki-Shi | Japan | 216-8511 | |
| 89 | Kagawa University Hospital | Kita-Gun | Japan | 761-0793 | |
| 90 | Kumamoto University Hospital | Kumamoto | Japan | 860-8556 | |
| 91 | Iwate Medical University Hospital | Morioka-shi | Japan | 020-8505 | |
| 92 | National Hospital Organization Nagoya Medical Center | Nagoya-shi | Japan | 460-0001 | |
| 93 | Niigata City General Hospital | Niigata | Japan | 950-1197 | |
| 94 | Hyogo College of Medicine Hospital | Nishinomiya-Shi | Japan | 663-8501 | |
| 95 | Kindai University Hospital | Osaka-Sayama-shi | Japan | 589-8511 | |
| 96 | Sapporo Medical University Hospital | Sapporo | Japan | 0608556 | |
| 97 | Hokkaido Medical Center | Sapporo | Japan | 063-0005 | |
| 98 | National Hospital Organization Sendai Medical Center | Sendai-City | Japan | 983-8520 | |
| 99 | Tokushima University Hospital | Tokushima | Japan | 770-8503 | |
| 100 | Tokyo Medical University Hospital | Tokyo | Japan | 160-0023 | |
| 101 | Teikyo University Hospital | Tokyo | Japan | 173-8606 | |
| 102 | Pusan National University Hospital | Busan | Korea, Republic of | 49241 | |
| 103 | Kyungpook National University Chilgok Hospital | Daegu | Korea, Republic of | 41404 | |
| 104 | Kyungpook National University Hospital | Daegu | Korea, Republic of | 41944 | |
| 105 | Korea University Medical Center (KUMC) - Korea University Anam Hospital | Seoul | Korea, Republic of | 02841 | |
| 106 | Severance Hospital, Yonsei University Health System | Seoul | Korea, Republic of | 120-752 | |
| 107 | Pusan National University Yangsan Hospital | Yangsan-si | Korea, Republic of | 50612 | |
| 108 | iBiomed Research Unit | Aguascalientes | Mexico | 20010 | |
| 109 | Consultorio Dr. Miguel Cortes | Cuernavaca | Mexico | 62448 | |
| 110 | Hospital Civil de Guadalajara Fray Antonio Alcalde | Guadalajara | Mexico | 44280 | |
| 111 | Neurocentrum Bydgoszcz Sp Z O O | Bydgoszcz | Poland | 85-796 | |
| 112 | NZOZ Wielospecjalistyczna Poradnia Lekarska 'Synapsis' | Katowice | Poland | 40-123 | |
| 113 | Centrum Neurologii Klinicznej, Krakowska Akademia Neurologii | Krakow | Poland | 31-505 | |
| 114 | Uniwersytecki Szpital Kliniczny nr 1 im. N. Barlickiego Uniwersytetu Medycznego w Łodzi | Lodz | Poland | 90-153 | |
| 115 | Centrum Neurologii Krzysztof Selmaj | Lodz | Poland | 90-324 | |
| 116 | Prywatny Gabinet Lekarski | Lublin | Poland | 20-093 | |
| 117 | Centrum Medyczne Neuromedica | Warsaw | Poland | 01-684 | |
| 118 | Hosp. Gral. Univ. de Alicante | Alicante | Spain | 03010 | |
| 119 | Hosp. de La Santa Creu I Sant Pau | Barcelona | Spain | 08025 | |
| 120 | Hosp. Univ. Vall D Hebron | Barcelona | Spain | 08035 | |
| 121 | Hosp. Clinic I Provincial de Barcelona | Barcelona | Spain | 8036 | |
| 122 | Hosp. Univ. de Basurto | Bilbao | Spain | 48013 | |
| 123 | Hosp. Gral. Univ. Gregorio Marañon | Madrid | Spain | 28007 | |
| 124 | Hosp. Virgen Macarena | Sevilla | Spain | 41009 | |
| 125 | Hosp. Virgen Del Rocio | Sevilla | Spain | 41013 | |
| 126 | Hosp. Univ. I Politecni La Fe | Valencia | Spain | 46026 | |
| 127 | Karlstad Central Hospital | Karlstad | Sweden | 651 85 | |
| 128 | Karolinska Universitetssjukhuset Solna | Stockholm | Sweden | 171 76 | |
| 129 | Chang Gung Memorial Hospital Kaohsiung Branch | Kaohsiung | Taiwan | 833 | |
| 130 | China Medical University Hospital | Taichung | Taiwan | 40447 | |
| 131 | Shin Kong Wu Ho Su Memorial Hospital | Taipei | Taiwan | 111 | |
| 132 | Taipei Veterans General Hospital | Taipei | Taiwan | 11217 | |
| 133 | University Hospitals Birmingham NHS Foundation Trust | Birmingham | United Kingdom | B15 2TH | |
| 134 | St George's Hospital | London | United Kingdom | SW17 0QT | |
| 135 | Sheffield Teaching Hospitals NHS Foundation Trust | Sheffield | United Kingdom | S10 2 JF |
Sponsors and Collaborators
- Janssen Research & Development, LLC
Investigators
- Study Director: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CR109046
- 2020-005732-29
- MOM-M281-011